Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 Monotherapy in Advanced Cervical Cancer
NCT06226350Phase 2Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in Cervical Cancer (CC), sponsored by Shandong New Time Pharmaceutical. Started Mar 2021; status: completed.
02
Drugs
rulonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06226350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226350.